{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-133250","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.646586+00:00","generated_at":"2026-05-15T08:06:20.994325+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SCYNEXIS acquires PXL-770 (SCY-770) from Poxel for $8M upfront, up to $188M total","bullets":["Asset includes direct AMPK activator PXL-770, now SCY-770, for ADPKD, with Orphan Drug Designation from FDA.","Upfront payment of $8M; potential development milestones up to $8M and commercial milestones up to $180M.","Phase 2 proof-of-concept study in ADPKD expected to start Q4 2026; early efficacy readout anticipated H2 2027.","SCY-770 has been evaluated in eight clinical trials with a favorable safety profile and targets underlying ADPKD drivers.","SCYNEXIS plans to host a conference call on March 31, 2026 at 8:30 AM ET to discuss the acquisition and corporate update."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-133250","json":"https://secwatch.observer/filing/0001193125-26-133250.json","markdown":"https://secwatch.observer/filing/0001193125-26-133250.md","text":"https://secwatch.observer/filing/0001193125-26-133250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/0001193125-26-133250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/d118823d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:06:20.994325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d26b495afe078cbdb3e5509886ef00b0e03d71bf","claim":"SCYNEXIS INC entered into Asset Purchase Agreement with Poxel SA valued at $8,000,000 (effective 2026-03-30).","evidence_excerpt":"On March 30, 2026, SCYNEXIS, Inc. (the “Company”) and Poxel SA, a French corporation (“Poxel”), entered into an asset purchase agreement (the “Asset Purchase Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/0001193125-26-133250-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Poxel SA"},{"label":"Value","value":"$8,000,000"},{"label":"Effective","value":"2026-03-30"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}